期刊
ANNALS OF SURGICAL ONCOLOGY
卷 13, 期 5, 页码 685-691出版社
SPRINGER
DOI: 10.1245/ASO.2006.03.010
关键词
micrometastasis; breast cancer; neoadjuvant therapy; lymph node metastasis; tumor dormancy
资金
- NCI NIH HHS [P50-CA 58223, 1 K08 CA098034-01A2] Funding Source: Medline
- NCRR NIH HHS [M01RR00046] Funding Source: Medline
- NIGMS NIH HHS [T32 GM008716] Funding Source: Medline
The prognostic significance of micrometastasis after neoadjuvant chemotherapy for locally advanced breast cancer is unknown. We examined the residual lymph node metastasis size in patients after treatment with neoadjuvant chemotherapy to determine the relevance of metastasis size on outcome. Stage II/III breast cancer patients treated with neoadjuvant chemotherapy at our institution from 1991 to 2002 were included. We examined the relationship of postneoadjuvant chemotherapy lymph node metastasis size and number with distant disease-free survival (DDFS) and overall survival (OS). In 122 patients with a median follow-up of 5.4 years, we found not only that patients with an increasing number of residual positive nodes had progressively worse DDFS and OS (P < .0001 for both) compared with patients with negative nodes, but also that the size of the largest lymph node metastasis was associated with worse DDFS and OS (P < .0001 for both) in both univariate and multivariate analysis. Compared with negative nodes, even lymph node micrometastasis (< 2 mm) was associated with worsened DDFS and OS (adjusted P = .02 and P = .005, respectively). Residual micrometastatic disease in the axillary lymph nodes after neoadjuvant chemotherapy is predictive of worse prognosis than negative nodes. In this study, the lymph node metastasis size and the number of involved lymph nodes were independent powerful predictors of DDFS and OS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据